CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to BioTime, Inc.	$ (10,429,121)	$ (7,642,222)
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:
Depreciation expense	183,981	128,215
Amortization of intangible assets	1,123,431	1,041,520
Amortization of deferred license and royalty revenues	(62,781)	(102,129)
Amortization of deferred consulting fees	388,124	388,124
Amortization of deferred license fees	87,434	54,750
Amortization of deferred rent	(5,427)	32,403
Amortization of deferred grant income	(261,777)	0
Stock-based compensation	614,505	560,082
Options: issued as independent director compensation	314,752	286,191
Write off of security deposit	(3,570)	0
Write off of expired inventory	0	1,510
Loss on sale/write off of equipment	3,546	0
Reduction in receivables from the reversal of revenues	205,004	0
Net loss allocable to noncontrolling interest	(1,796,378)	(1,302,379)
Changes in operating assets and liabilities:
Accounts receivable, net	(143,044)	(121,922)
Grant receivable	0	261,777
Inventory	(3,844)	25,425
Prepaid expenses and other current assets	497,503	127,621
Accounts payable and accrued liabilities	(373,555)	139,334
Other long-term liabilities	(13,462)	(32,795)
Deferred revenues	0	(22,873)
Deferred grant income	0	24,462
Net cash used in operating activities	(9,674,679)	(6,152,906)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(153,490)	(537,959)
Payment of license fee	0	(1,500)
Cash paid, net of cash acquired for assets	0	(246,850)
Cash acquired in connection with mergers	292,387	5,908
Proceeds for the sale of equipment	4,500	0
Security deposit (paid)/received	(526)	248
Net cash provided by (used in) investing activities	142,871	(780,153)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the exercise of stock options from employees	14,800	80,553
Proceeds from the exercise of stock options from directors	0	112,328
Proceeds from the exercise of stock options from outside consultant	0	4,700
Proceeds from the exercise of warrants	0	416,300
Proceeds from the sale of common shares of subsidiary	0	213,500
Cash provided by financing activities	14,800	827,381
Effect of exchange rate changes on cash and cash equivalents	(35,046)	162,695
NET CHANGE IN CASH AND CASH EQUIVALENTS:	(9,552,054)	(5,942,983)
Cash and cash equivalents at beginning of period	22,211,897	33,324,924
Cash and cash equivalents at end of period	12,659,843	27,381,941
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	255	880
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:
Common shares issued in connection with the purchase of assets	0	2,300,000
Common shares issued as part of merger	1,802,684	2,600,000
Common shares issued as part of acquisition	0	0
Warrants issued as part of merger	$ 0	$ 954,879